首頁 › 非小細胞肺癌 › 俄亥俄州 › Cincinnati
Cincinnati, OH 的 非小細胞肺癌 臨床試驗
35 項針對 非小細胞肺癌 的研究正在 Cincinnati（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
招募中3 期
- University of Cincinnati Medical Center ( Site 0119), Cincinnati
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
招募中3 期
- The Christ Hospital, Cincinnati
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
招募中3 期
- Local Institution - 0383, Cincinnati
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
招募中3 期
- University of Cincinnati Cancer Center, Cincinnati
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
招募中3 期
- TriHealth Cancer & Blood Institute Research, Cincinnati
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
招募中3 期
- Oncology_Hematology Care Clinical Trials,LLC, Cincinnati
- Oncology_Hematology Care Clinical Trials,LLC, Cincinnati
- Oncology_Hematology Care Clinical Trials,LLC, Cincinnati
- 還有 1 項
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
招募中3 期
- Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0061), Edgewood · 距離 8 英里
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
招募中3 期
- Oncology Hematology Care Clinical Trials, Cincinnati
- Oncology Hematology Care Clinical Trials, Cincinnati
- Oncology Hematology Care Clinical Trials, Cincinnati
- 還有 1 項
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
招募中2 期
- Cincinnati Veterans Affairs Medical Center, Cincinnati
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
招募中3 期
- University of Cincinnati Medical Center, Cincinnati
- Saint Elizabeth Medical Center Edgewood, Edgewood · 距離 8 英里
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
招募中3 期
- Research Site, Cincinnati
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
招募中2/3 期
- The Christ Hospital Cancer Center, Cincinnati
- University of Cincinnati Medical Center, Cincinnati
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
招募中3 期
- Saint Elizabeth Medical Center Edgewood, Edgewood · 距離 8 英里
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
招募中3 期
- Research Site, Cincinnati
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
招募中3 期
- Clinical Study Sites, Cincinnati
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
招募中2/3 期
- Local Institution - 007-893-B, Cincinnati
- USOR - Oncology Hematology Care - Blue Ash, Cincinnati
- Local Institution - 007-893-C, Cincinnati
- 還有 1 項
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
招募中2/3 期
- Oncology Hematology Care, Inc - Blue Ash /ID# 262733, Cincinnati
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
招募中1/2 期
- Christ Hospital, Cincinnati
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
招募中3 期
- University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0103), Cincinnati
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
招募中3 期
- USO - Oncology Hematology Care, Cincinnati
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
招募中1 期
- University of Cincinnati (UC) - Cancer Institute, Cincinnati
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
招募中1 期
- St. Elizabeth Healthcare, Edgewood · 距離 8 英里
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
招募中3 期
- University of Cincinnati Medical Center, Cincinnati
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
招募中2 期
- University of Cincinnati Medical Center, Cincinnati
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
招募中1/2 期
- University of Cincinnati, Cincinnati
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
招募中1 期
- The Christ Hospital, Cincinnati
MYLUNG Consortium Part 3: Observational Study
招募中觀察性研究
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
招募中1/2 期
- Christ Hospital Cancer Center, Cincinnati
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
招募中2 期
- St. Elizabeth Healthcare, Edgewood · 距離 8 英里
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
招募中1/2 期
- Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center, Cincinnati
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
招募中
- University of Cincinnati Medical Center, Cincinnati
GEMINI-NSCLC: NSCLC Biomarker Study
招募中觀察性研究
- TriHealth Cancer Institute, Cincinnati
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
招募中1/2 期
- Research Site 113, Cincinnati
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Cincinnati
A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.
招募中2 期
- The Christ Hospital, Cincinnati
其他城市的 非小細胞肺癌 試驗
- Houston, TX145 項研究
- New York City, NY120 項研究
- Arlington, VA104 項研究
- Nashville, TN97 項研究
- Boston, MA90 項研究
- Los Angeles, CA87 項研究
- St. Louis, MO73 項研究
- Chicago, IL61 項研究
- Baltimore, MD60 項研究
- San Antonio, TX59 項研究
- Columbus, OH56 項研究
- Washington, DC55 項研究
Cincinnati 的其他研究
- 癌症（所有類型）27 項研究
- 乳癌25 項研究
- 心臟衰竭24 項研究
- 大腸直腸癌21 項研究
- 急性髓系白血病20 項研究
- 轉移性癌症20 項研究
- 卵巢癌19 項研究
- 肺癌19 項研究
- 肥胖症19 項研究
- 前列腺癌18 項研究
- 多發性骨髓瘤17 項研究
- 黑色素瘤17 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。